Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis

doi:10.4330/wjc.121611

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(25)

(24)

(0)

(372)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Cardiol. Jul 26, 2026; 18(7): 121611
Published online Jul 26, 2026. doi: 10.4330/wjc.121611

Full Size Figure Download Figure

Figure 5 Overall safety outcomes. A and B: Dose comparison of olezarsen 80 mg vs 50 mg in regard to any adverse events (A) and serious adverse events (B).

Citation: Patel V, Sohail R, Alam M, Chaudhry S, Mehdi S, Patel S, Patel R, Khattak R, Khan Z, Patel M. Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis. World J Cardiol 2026; 18(7): 121611
URL: https://www.wjgnet.com/1949-8462/full/v18/i7/121611.htm
DOI: https://dx.doi.org/10.4330/wjc.121611

Patel V, Sohail R, Alam M, Chaudhry S, Mehdi S, Patel S, Patel R, Khattak R, Khan Z, Patel M. Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis. World J Cardiol 2026; 18(7): 121611 [DOI: 10.4330/wjc.121611]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.